Employees
~50
Stage
Phase 1
Modalities
Medical devices

Amber Therapeutics General Information

First-in-human AURA-2 study with 13 women showed safety and feasibility of surgical procedure, with strong efficacy signals in both mixed urinary incontinence and severe refractory urge incontinence patients

Contact Information

Website
Primary Industry
Medical Devices
Corporate Office
London,
United Kingdom

Drug Pipeline

Amber-UI
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Amber Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Amber Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Amber Therapeutics's complete valuation and funding history, request access »